Rebecca Dryer-Minnerly

Rebecca Dryer-Minnerly has a wealth of experience in the field of biomedicine. Rebecca began their career in 1998 as a Medical Technologist at Capital Health System. In 2001, they became a Doctoral Research & Teaching Assistant at Rutgers University, where they characterized promoter sequences and protein complexes regulating class switch recombination in human B-lymphocytes. From 2007-2020, they were employed at Johnson & Johnson, first as a Postdoctoral Research Fellow and then as a Biomarker Research Scientist Inflammatory Diseases, where they designed strategies to demonstrate target engagement and pharmacodynamic effects of novel therapeutics in rheumatologic diseases. From 2016-2020, they worked at Adaptimmune, first as a Senior Scientist, Translational Sciences and then as a Principal Scientist, Translational Sciences, where they served as the translational project team lead in support of SPEAR-T cell therapies targeting solid tumors. Finally, in 2020 they became the Director of Translational Medicine at Tmunity Therapeutics Incorporated, where they built core translational capabilities and supported the development of Ph1 studies employing CART-TnMUC1 for the treatment of various cancers. In 2021, Rebecca began their current role as Director of Preclinical Research at Cabaletta Bio.

Rebecca Dryer-Minnerly has a Doctor of Philosophy from the University of Medicine and Dentistry of New Jersey & Rutgers State University, Department of Cell Biology and Neuroscience, which they obtained between 2001 and 2006 in the field of Immunology, Microbiology and Molecular Genetics. Rebecca also has a Medical Technologist (MT ASCP) from Carilion Roanoke Memorial Hospital, School of Clinical Laboratory Science, which they obtained between 1997 and 1998 in the field of Clinical Science. Lastly, they have a B.S. Biology from Virginia Tech, which they obtained between 1993 and 1997 in the field of Microbiology & Immunology. Additionally, they have a MT ASCP certification from Virginia Tech Carilion School of Medicine, which they obtained in July 1998.